Actively Recruiting
Phase 2 Study to Test Safety and Effectiveness of Three Dose Levels of NMD670 Over 21 Days in Adults With Myasthenia Gravis Having AChR or MuSK Antibodies
Led by NMD Pharma A/S · Updated on 2026-07-01
84
Participants Needed
40
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effects of three different dose levels of NMD670 in adult patients with Myasthenia Gravis who have antibodies against AChR or MuSK. This Phase 2 study is designed to find the appropriate dose and understand how the drug compares to a placebo over 21 days of treatment. The study focuses on adults diagnosed with moderate to severe forms of Myasthenia Gravis. Participants will receive one of three doses of NMD670 or a placebo, taken as tablets twice a day for 21 days. The study randomly assigns participants to these groups and is conducted under a double-blind method so that neither participants nor researchers know which treatment is given. The trial evaluates the effects of NMD670 on muscle strength and daily living activities using several rating scales. During the study, participants will be monitored for changes in their muscle strength and symptoms using specific clinical scores from the start of treatment to day 21. Safety assessments will include physical exams, laboratory tests, vital signs, ECGs, and eye exams before and after treatment. Researchers will also track any side effects or serious events during the dosing period. Participation will last about three weeks with close medical follow-up to assess the study drugs impact.
CONDITIONS
Brief Title
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Research Team
N
NMD Pharma A/S
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
